President Trump directed CMS Administrator Dr. Mehmet Oz to halt federal Medicaid and CHIP funding for puberty blockers, cross-sex hormones, and surgeries on minors, a rule set to take effect October 13.
Trump announced the policy shift Tuesday in a Truth Social post, calling the procedures "barbaric" and framing the move as a direct order to Oz to stop taxpayer dollars from covering gender transition interventions for children. The Centers for Medicare and Medicaid Services followed with a formal statement confirming it will implement a rule ending all federal Medicaid and Children's Health Insurance Program funding for those procedures.
The rule covers puberty blockers, cross-sex hormones, and surgical operations. It does not restrict coverage for mental health services, including psychotherapy, for children diagnosed with gender dysphoria. CMS stated that the procedures targeted by the rule "can result in irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects."
Roughly 34.5 million children are enrolled in Medicaid and CHIP nationwide, according to the Washington Examiner, making the scope of the funding prohibition sweeping. For children already receiving hormone treatments, a six-month tapering period will allow continued coverage through April 2027, giving families and providers time to adjust.
The administration grounded its action in a Department of Health and Human Services review of national and international research. That review found "significant evidence gaps, documented serious safety concerns, and concluded that the evidence supporting these interventions for children remains insufficient to justify federal taxpayer funding."
CMS also pointed to the 2024 Cass Review, an independent British study led by Dr. Hilary Cass, as a cornerstone of its reasoning. The Cass Review concluded that research on cross-sex hormones and puberty blockers was "limited and not definitive" and that medical interventions had developed significantly faster than the evidence proving those interventions were safe. That finding from across the Atlantic gave the administration a credible, non-partisan scientific basis for the policy, one produced outside the American political arena entirely.
Twenty-seven states have already enacted their own restrictions on gender-affirming care for minors, according to KFF, a health policy group. Many major hospitals have also stopped providing some of these treatments. The federal rule now aligns Medicaid policy with the direction most state legislatures have already moved.
Trump's administration has been aggressive in using federal funding as a lever across multiple policy areas, from health care to election security. This latest action fits a pattern: when the evidence doesn't support the spending, the spending stops.
Dr. Oz, the CMS administrator, framed the rule as both a scientific and fiscal matter. Fox News Digital reported his statement:
"Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish."
HHS Secretary Robert F. Kennedy Jr. also weighed in. The New York Post reported Kennedy's statement: "Today, we are ending federal taxpayer funding for sex-rejecting procedures on children. These interventions carry serious risks and can cause irreversible harm."
HHS Press Secretary Emily Hilliard reinforced the administration's position in a statement to Fox News Digital:
"The Trump Administration is drawing a clear line: America's children will not be subjected to life-altering interventions on the taxpayer's dime without reliable evidence of safety and clinical benefit."
Hilliard added that "American taxpayers should never be forced to finance interventions when the evidence of benefit is insufficient and the potential consequences for children can be serious and irreversible." She emphasized that under Kennedy's leadership, federal health care dollars would support evidence-based care that "puts their long-term health first."
The administration's broader effort to root out waste and misuse of taxpayer funds has already produced results elsewhere. Vice President Vance's fraud task force has blocked $56 billion in bogus payments across federal programs, a signal that the White House sees fiscal discipline and program integrity as connected fights.
The rule drew immediate opposition from LGBTQ+ advocacy organizations. Human Rights Campaign President Kelley Robinson told the AP: "The Trump administration is terrorizing trans youth and their families with these kinds of actions, and it has to stop."
GLBTQ Legal Advocates and Defenders also vowed to pursue legal challenges to the policy. But the administration's approach, building the rule on an HHS evidence review and the internationally recognized Cass Review, appears designed to withstand exactly that kind of court fight. When the government's own research arm says the evidence doesn't support the spending, a legal challenge faces a steep climb.
Democrats have characterized the administration's actions on transgender policy as "attacks against trans people." But the rule itself is narrowly drawn. It targets specific medical and surgical interventions on minors, not adults, not mental health services, not therapy. It is a funding decision, not a blanket prohibition on care.
Separately, the Trump administration has cut federal funding to New York's Medicaid fraud unit after criminal enforcement there collapsed, another example of the White House holding states accountable for how federal health care dollars are spent.
Trump did not limit his Truth Social post to the policy announcement. He drew a direct contrast with Democrats ahead of the November midterm elections.
"While the Democrat Party wants your kids to be able to chop off their reproductive organs before they are old enough to vote."
He also noted that many hospitals across the country have already ended such procedures, with more expected to follow. The president urged his followers to remember the Democratic Party's position when they head to the polls.
The political calculation is straightforward. Polls consistently show that the public, including many moderates and independents, is deeply uncomfortable with irreversible medical procedures on children. By forcing Democrats to defend taxpayer-funded puberty blockers and surgeries on minors, the administration puts its opponents on the wrong side of a question most parents answer the same way.
The administration has shown a willingness to tie federal funding to policy compliance across multiple fronts, from election security to health care. The Medicaid rule fits that pattern: federal money comes with federal standards, and those standards now reflect the available evidence rather than ideological pressure.
Breitbart reported that the policy is part of a broader series of executive actions targeting transgender policies since Trump returned to office. The Medicaid rule, however, stands on its own merits, grounded in an international evidence review, limited to minors, and preserving mental health coverage.
HHS also initiated a separate rule-making process that would condition hospital participation in Medicare and Medicaid on not providing sex-trait modifications to minors, National Review reported. That rule remains in the final stage of White House review and would extend the prohibition beyond direct Medicaid reimbursement to the institutional level.
When the science doesn't support the procedure, and the patient can't legally consent to a tattoo, the question answers itself. The only mystery is why taxpayers were footing the bill in the first place.